Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lineage Cell Therapeutics, Inc. (LCTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. Lineage is incorporated in California and its common stock trades on the NYSE American under the symbol LCTX. Through periodic and current reports, investors can review how the company describes its allogeneic, or “off the shelf,” cell therapy programs, its proprietary pluripotent cell–based platform, and its development and manufacturing activities.
Among the most relevant documents for analysis are Lineage’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically summarize its pipeline, including OpRegen retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration, OPC1 oligodendrocyte progenitor cell therapy for spinal cord injuries, ReSonance (ANP1) for hearing loss, PNC1 for potential treatment of vision loss, the RND1 hypoimmune induced pluripotent stem cell line, and the ILT1 islet cell transplant initiative for Type 1 Diabetes. These filings also discuss the company’s proprietary manufacturing approaches, such as its two-tiered cGMP cell banking system and AlloSCOPE framework.
Current reports on Form 8-K provide timely details on material events, including collaboration agreements, clinical and manufacturing milestones, equity financings, and governance matters. Recent 8-K filings describe, for example, a development milestone payment under the Roche and Genentech collaboration for OpRegen, a research collaboration agreement with William Demant Invest A/S for ReSonance, capital raised through a block transaction under an at-the-market offering program, and updates related to grant applications for the OPC1 program.
On Stock Titan, these filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, helping users quickly identify disclosures related to clinical progress, collaboration economics, equity issuances, and shareholder approvals. Investors can also monitor additional SEC forms, such as proxy materials referenced in 8-K filings, to better understand Lineage’s equity incentive plans and shareholder voting outcomes.
Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share. Following these purchases, he directly holds 255,516 common shares.
Lineage Cell Therapeutics, Inc. is registering up to $100,000,000 of securities to sell from time to time under a shelf registration. The registration covers common shares, preferred shares, debt securities and warrants, and securities issuable upon conversion or exercise, with specific terms to be provided in prospectus supplements.
The company states its common shares trade on the NYSE American and the TASE under the symbol LCTX, and reports a last NYSE American sale price of $1.77 per share on March 9, 2026. Proceeds treatment and offering mechanics will be described in each prospectus supplement; the prospectus permits sales directly, through agents, or via underwriters and contemplates at-the-market and other distribution methods.
Lineage Cell Therapeutics, Inc. filed a new prospectus supplement to support an at-the-market offering of its common shares with an aggregate offering price of up to $60,000,000 through or to B. Riley Securities, Inc. This program is under an existing Form S-3 shelf registration and sales agreement framework and excludes $22,583,663.82 in common shares already sold under prior prospectus supplements.
Ligand Pharmaceuticals, Inc. amends its prospectus supplement to increase the aggregate amount of common shares it may sell under its at-the-market sales agreement with B. Riley Securities, Inc. to $60,000,000. The supplement states this raises the ceiling for sales under the Sales Agreement dated March 22, 2024.
The supplement notes $22,583,663.82 in aggregate gross sales have been sold under the prior supplements and base prospectus to date. The filing also discloses the last reported NYSE American sale price of the common shares was $1.77 per share on March 9, 2026. The offering is subject to the Base Prospectus, prior supplements and the risk factors already disclosed.
Lineage Cell Therapeutics reported that its President and CEO, Brian M. Culley, received a grant of stock options covering 3,250,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the terms, one quarter of these options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments thereafter, contingent on continued employment. Following this award, Culley holds 3,250,000 stock options directly.
Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026. These options carry a stated exercise price of $0.0000 per share, reflecting a compensatory award rather than an open-market purchase.
According to the terms, one quarter of the options will vest on March 5, 2027. The remaining three quarters will then vest in 36 equal monthly installments, contingent on the completion of each month of continuous employment. Following this grant, Howe’s directly held option position from this award totals 1,050,000 options.
Samuel George A. III reported acquisition or exercise transactions in this Form 4 filing.
Lineage Cell Therapeutics, Inc. reported that its General Counsel and Secretary, Samuel George A. III, received a grant of 900,000 employee stock options on March 5, 2026. These options were awarded at no purchase price at grant as part of his compensation.
According to the vesting terms, one quarter of the options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments after that date, contingent on continuous employment each month.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell replacement therapies to treat serious conditions caused by loss or dysfunction of specific cell types, an approach it calls “Replace and Restore.” All programs are built on its proprietary AlloSCOPE manufacturing platform for scalable, off‑the‑shelf pluripotent cell-derived products.
The lead asset, OpRegen (RG6501), an allogeneic retinal pigment epithelial therapy for geographic atrophy secondary to dry age-related macular degeneration, is partnered worldwide with Roche and Genentech. Lineage received a $50.0 million upfront payment and a $5.0 million development milestone, and remains eligible for up to $615.0 million in additional milestones plus tiered double‑digit royalties.
Lineage’s wholly owned pipeline includes OPC1 for spinal cord injury, which has RMAT and Orphan Drug designations and is being evaluated in the DOSED clinical study using a novel delivery device, and ReSonance (ANP1) for hearing loss, supported by a collaboration with William Demant Invest funding up to $12 million in preclinical work. Additional earlier initiatives target Type 1 diabetes manufacturing scale (ILT1), a hypoimmune iPSC line (RND1), and photoreceptor replacement (PNC1). As of March 5, 2026, Lineage had 249,087,529 common shares outstanding.
Lineage Cell Therapeutics reported higher revenue but a much larger net loss for 2025 while extending its cash runway and advancing its cell therapy pipeline. Total revenues for the year ended December 31, 2025 were $14.6 million, up from $9.5 million in 2024, mainly from collaboration revenue with Roche and a new research collaboration with William Demant Invest.
Total operating expenses rose to $51.2 million, including a $14.8 million impairment of an intangible asset related to the VAC platform. A large non-cash fair value remeasurement expense of warrant liabilities contributed to other expense of $32.0 million, versus other income of $2.9 million in 2024. Net loss attributable to Lineage widened to $63.5 million, or $0.28 per share, compared to $18.6 million, or $0.09 per share.
As of December 31, 2025, cash, cash equivalents and marketable securities were $55.8 million. Together with approximately $5.4 million in warrant exercise proceeds in March 2026, management expects this to fund planned operations into the second quarter of 2028. Operationally, the company achieved its first OpRegen milestone under its collaboration with Roche and Genentech, reported positive 36‑month OpRegen Phase 1/2a data, demonstrated high-scale AlloSCOPE manufacturing, secured up to $12 million of planned ReSonance (ANP1) preclinical funding from William Demant Invest, and treated the first chronic spinal cord injury patient in the OPC1 DOSED study.